Isolated aPTT of 112 Seconds on a Patient with a Central Line
A 68-year-old man is admitted with melena and a hemoglobin of 7.2 g/dL. He has a triple-lumen central catheter flushed with heparin 100 U/mL after each use. Admission coagulation testing on a sample drawn by the night nurse from the distal lumen shows PT 13.1 s (reference 11.0–13.5), aPTT 112 s (reference 25–35), fibrinogen 420 mg/dL and platelets 205 × 10⁹/L. He takes no anticoagulants and has no personal or family history of bleeding or thrombosis. A repeat aPTT on a sample drawn from the left antecubital vein four hours later is 31 s. The first specimen was not labeled with the draw site. He is scheduled for endoscopy, and the anesthesiologist wants to know whether fresh frozen plasma should be given before the procedure.
1. Explain the discrepancy and describe the confirmatory testing you would perform on the first specimen.
Read the worked answer
The first specimen is almost certainly contaminated with heparin from the catheter flush. The clues are an isolated aPTT prolongation with a normal PT, a normal fibrinogen, no anticoagulant history, and a normal peripheral repeat four hours later. A true factor deficiency or a specific inhibitor does not normalize spontaneously within four hours without treatment.
Confirmatory testing on the original specimen: (1) thrombin time - markedly prolonged even by trace heparin, whereas reptilase time is normal because reptilase is not inhibited by heparin; the thrombin/reptilase discordance is the classic signature. (2) Anti-Xa activity - elevated, and it quantifies the contamination. (3) Heparin neutralization - repeat the aPTT after adding protamine or heparinase; correction to normal confirms heparin. Do not interpret individual factor VIII or IX assays on this sample, because heparin produces falsely low factor activity and can mimic a deficiency.
2. What is the appropriate transfusion decision, and what do you tell the anesthesiologist?
Read the worked answer
No fresh frozen plasma. There is no coagulopathy to correct: the PT, fibrinogen and platelet count are normal and the peripheral aPTT is 31 s. Plasma would expose the patient to transfusion-associated circulatory overload and TRALI risk with no possible benefit, and it would not treat the actual problem.
The bleeding is a gastrointestinal hemorrhage with a hemoglobin of 7.2 g/dL; management is red cell transfusion and endoscopic hemostasis, along with review of any antiplatelet agents or NSAIDs. The message to the anesthesiologist should be explicit: the abnormal aPTT was a preanalytical artifact from a line draw, confirmed by a normal peripheral sample and by heparin-sensitive tests, and the corrected result should be entered in the record with a comment so it is not re-interpreted later.
3. What system changes would reduce recurrence?
Read the worked answer
First, stop drawing coagulation samples from lines whenever a peripheral vein is available; when a line is unavoidable, use a documented discard volume or a separate-syringe technique and record the draw site on the requisition and in the LIS.
Second, build a laboratory hold rule: any isolated, unexplained aPTT prolongation beyond a defined threshold triggers a call to the unit requesting a peripheral redraw rather than automatic reporting. Add reflex thrombin time and reptilase time to the protocol.
Third, educate nursing staff on heparin flushes and their effect on coagulation testing, and audit the proportion of coagulation samples received from lines. Fourth, require two-sample verification before any plasma product is released for an isolated aPTT abnormality. Each of these is inexpensive and targets the actual failure, which was specimen provenance rather than the assay.